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Abstract 
OBJECTIVE:  It is well documented that the most common problems associated with diagnostic 
and interventional angiography are major bleeding and vascular complications. While previous 
research and the American College of Cardiology (ACC) recommend the use of bleeding risk 
stratification tools, there is little evidence related to the use of bleeding avoidance strategies in 
the high-risk for bleeding population.  This study aims to determine if individualizing access site 
and anticoagulation strategies based on bleeding risk stratification would positively impact 
NCDR Risk-Adjusted Bleeding Rates.  
METHODS:  This was a single-center pilot study utilizing retrospective chart reviews with 
pre/post design.  Data was collected on all percutaneous coronary interventions (PCI) from 3 
interventionalists excluding ST elevation myocardial infarction (STEMI) and staged chronic total 
occlusion (CTO) procedures.  Variables analyzed in the study included age, gender, body mass 
index (BMI), bleeding risk score, access site, anticoagulation strategy, P2Y12 inhibitor used, use 
of GPIIbIIIa inhibitors, use of vascular closure devices, ultrasound use, bleeding events, blood 
transfusions and the previous diagnosis of heart failure, end-stage renal disease, and diabetes 
mellitus.  The study compared baseline data (3 months prior to implementation) to post 
implementation data (3 months after implementation).   
RESULTS:  High bleeding risk patients comprised 14% and 18% of the baseline and post 
implementation groups respectively; after exclusion criteria was considered, only 9.4% and 
10.7% of the PCI subjects were utilized for analysis.  Sample sizes were too small to show 
statistically significant differences between the baseline and post implementation groups.   
CONCLUSION: Further research is necessary to directly correlate the benefits of individualizing 
patient care based on bleeding risk stratification.
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Individualizing Patient Care During Percutaneous Coronary Intervention to Reduce Operator 
Risk Adjusted Bleeding Rates: A Pre/Post Interventional Study 
Background 
 Peri-procedural bleeding is a serious risk for the percutaneous coronary intervention 
(PCI) patient population.  Therefore, as Singh (2015) states, “recognition and mitigation of 
bleeding risk following PCI is a recognized health care priority” (p. 2233).  Major bleeding and 
vascular complications are among the most common complications associated with diagnostic 
and interventional angiography (Nelson et al., 2018). Moreover, bleeding complications have 
long been cited as direct predictors of prolonged hospital stays, increased short and long-term 
morbidity and mortality, and significantly increased financial burden (Singh, 2015).  Among 
other factors, predictors of major bleeding include patients who are of advanced age, female, or 
with renal impairment (Singh, 2015).  Bleeding avoidance strategies (BAS) can be utilized to 
successfully improve quality of care in patients who are at high risk for major bleeding events.  
BAS include use of radial artery access rather than femoral artery when possible; use of 
bivalirudin rather and heparin with/without glycoprotein inhibitors; and the use of vascular 
closure devices after femoral access for PCI (Khambatta et al., 2016).  The American College of 
Cardiology (ACC) clinical practice guidelines recommend that all patients be evaluated for 
bleeding risk prior to PCI (Levine et al., 2011).  Bleeding risk scoring tools can be utilized to 
identify patients who are most at risk for major bleeding events and further individualize intra 
and post procedural care decisions to maximize patient safety (Kerl et al., 2015). 
The National Cardiovascular Data Registries (NCDR) CathPCI registry monitors and can 
be used to draw conclusions regarding major bleeding events in cardiac catheterization labs 
nationwide.  The CathPCI In-Hospital Risk Adjusted Rate of Bleeding (RAB) considers any post 
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PCI patient eighteen years or older with a post-PCI bleeding event.  The ACC defines post-PCI 
bleeding as any of the following: a bleeding event within 72 hours (arterial access site bleeding; 
retroperitoneal, gastrointestinal, or genitourinary bleeding); intracranial hemorrhage; cardiac 
tamponade; post-procedure hemoglobin decrease of > 4 g/dl and pre-procedure hemoglobin of < 
16 g/dl (Rao et al., 2013).  As of 2017, a widely known cardiovascular institution in the Midwest 
remains above the national benchmark for this measure.   
  Multiple tools have been shown to be effective in predicting PCI bleeding risk.  One 
validated tool used widely nationwide is the NCDR CathPCI Bleeding Risk Score.  This simple 
tool was derived from the national CathPCI database, and can be used in patients who present 
with acute coronary syndrome (ACS) or those who are undergoing elective angiography (Singh, 
2015).  The NCDR Bleeding Risk Score considers the patient’s presentation, status of ST 
elevated myocardial infarction (STEMI), age, body mass index (BMI), previous PCI, degree of 
renal dysfunction, presentation of shock, recent cardiac arrest, gender, and most recent 
hemoglobin result (Rao et al., 2013).  Bleeding risk is calculated based on a point system and 
categorized (low, intermediate, or high) based on the result.  This tool is currently utilized to 
evaluate all patients undergoing coronary angiography at the institution of interest for this study.  
Once bleeding risk stratification has been established, the operator and care team should utilize 
the information to improve patient safety.  Data suggest that the employment of BAS in patients 
who are at intermediate or high risk for bleeding both improves the safety of the procedure for 
vulnerable populations and decreases costs associated with PCI.   
 Because the risk for bleeding is modifiable (Singh, 2015), it is crucial that intermediate 
and high risk patients be identified and treated accordingly.  The purpose of this study is to 
utilize the Bleeding Risk Score to individualize arterial access and anticoagulation strategies to 
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decrease individual operator RAB rates.  This is a small pilot study in which the investigator will 
follow three high volume physicians and compare their bleeding complication rates before and 
after employing the patient appropriate BAS.  The question posed for this research is: What is 
the effect of using the NCDR CathPCI Bleeding Risk Score for individualized access site and 
anticoagulation strategies on individual operator RAB rate? 
This project proposes the use of BAS in the patient populations deemed at high risk for 
bleeding events peri-procedure. Singh (2015) suggests considering the following for those who 
are at increased risk of bleeding: (1) use of radial access; (2) aiming for activated clotting time 
(ACT) levels; (3) use of bivalirudin for high risk cases; (4) use of fluoroscopy, ultrasound and 
micropuncture techniques to guide femoral access; (5) early sheath removal; and (6) use of 
vascular closure devices.  The specific aim of this project is to provide evidence to determine if 
operator RAB rates are affected by employment of BAS.  A secondary goal of this project is to 
begin a shift among operators in this environment to utilize the bleeding risk score made 
available to them to maximize patient safety.  Applying evidence-based practice to the operator’s 
normal routine may decrease overall bleeding complications, improve patient outcomes, and 
minimize financial costs associated with adverse bleeding events.  
Theoretical Framework 
The Transtheoretical Model (TTM; Stages of Change) formed the theoretical framework 
for this study.  Applying the TTM helped us identify the stages of change that the operators faced 
while adapting to implement evidence-based practice.  The focus was on utilizing tools that are 
readily available to optimize patient safety and minimize peri-procedural complications.  Nelson 
et al. (2018) have discussed the operator preference of femoral access, the lack of use of adjunct 
imaging (fluoroscopy and ultrasound) for access, the minimal use of micropuncture needle kits, 
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and the preference of unfractionated heparin as opposed to bivalirudin.  The authors further 
discussed the disconnect between evidence and practice in this area: experience and comfort with 
outdated techniques continue, though evidence clearly shows that a change is warranted (Nelson 
et al., 2018). 
Review of Literature 
Methods 
 Thorough searches of the PubMed and Scopus databases were completed to obtain 
current research on vascular access complications, strategies to avoid bleeding complications, 
use of bleeding risk predictor tools, and comparison of the use of heparin versus bivalirudin in 
the setting of coronary intervention.  The inclusion criteria limited this literature review to 
studies and/or reviews published since 2013 to ensure that the most current and relevant 
literature was analyzed.  Keywords and phrases such as “vascular access complications,” 
“bleeding risk score,” “prevention AND complications AND vascular,” “coronary intervention,” 
and “bivalirudin AND heparin” were all used for database search purposes.  Several 
combinations of database search results were utilized to narrow search results further.  The 
search for evidence yielded a high-quality mixture of randomized controlled studies, systematic 
reviews and meta-analyses.  The search results were closely examined to include only the highest 
level of evidence, related specifically to identifying the high risk PCI population and strategies 
which can be employed to decrease vascular complications within this group.  
Minimizing Major Bleeding Complications 
 Despite the equipment and technology advances associated with PCI procedures, peri-
procedural bleeding remains one of the most common complications in this population (Gargiulo 
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et al., 2018; Khambatta et al., 2016; Mehran et al., 2010; Nelson et al., 2018; Numasawa et al., 
2017; Rao, Chhatriwalla et al., 2013; Singh, 2015).  More specifically, femoral artery access site 
bleeding and hematoma formation are the most common vascular complications associated with 
the procedure (Khambatta et al., 2016; Nelson et al., 2018; Pasala et al., 2016; Rashid et al., 
2017).  As more potent pharmacological treatment is introduced for prevention of thrombotic 
events peri-procedure, a consequence is increased hemorrhagic complications (Mehran et al., 
2010).  Bleeding complications following PCI have been correlated to higher patient morbidity 
and mortality, as well as prolonged hospitalization and increased costs (Dobies et al., 2015; 
Gargiulo et al., 2018; Khambatta et al., 2016; Mehran et al., 2010; Rao, Chhatriwalla et al., 2013; 
Rashid et al., 2017; Singh, 2015). Significant predictors of increased bleeding risk associated 
with PCI include older age, female gender, femoral artery access, low BMI, and renal 
impairment (Dobies et al., 2015; Gargiulo et al., 2018; Khambatta et al., 2016; Rao, McCoy et 
al., 2013; Singh, 2015).  Utilizing BAS in patient populations who are at highest risk for bleeding 
events has been associated with decreased rates of bleeding complications (Khambatta et al., 
2016; Mina, Gobrial, Modi, & Dominic, 2016; Nelson et al., 2018; Rao, Chhatriwalla et al., 
2013; Singh, 2015). 
Individualized Bleeding Risk Scoring Tools 
 Simple tools are available to assist providers in stratifying patients into groups based on 
the risk factors for increased bleeding events (Dobies et al., 2015; Kerl et al., 2015; Mehran et 
al., 2010; Rao, Chhatriwalla et al., 2013; Rao, McCoy et al., 2013). Various bleed risk 
stratification tools exist which utilize point systems for specific patient variables and determine 
that patient’s level of risk for peri-procedural bleeding.  These models are referred to as bleeding 
risk scores (BRS), and it is the NCDR PCI BRS that is most widely used throughout the United 
12 
States (Dobies et al., 2015; Kerl et al., 2015; Rao, Chhatriwalla et al., 2013; Rao, McCoy et al., 
2013).  The NCDR PCI BRS was derived from a logistic regression analysis utilized to 
determine the pre-PCI variables most predictive of bleeding in a PCI population of more than 
300,000 (Kerl et al., 2015).  The NCDR PCI BRS model has been updated as recently as 2013 to 
identify the most significant risk factors noted in contemporary clinical practice, making it a 
useful tool to guide clinical decision-making and support quality improvement (Kerl et al., 2015; 
Rao, McCoy et al., 2013).  
Radial Versus Femoral Access 
 Radial artery access certainly decreases bleeding complications among the PCI patient 
population and its use is on the rise (Jaswaney et al., 2018; Khambatta et al., 2016; Mina et al., 
2016; Rashid et al., 2017; Singh, 2015).  In a large survey conducted in 2016, a great portion 
(42%) of cardiologists considered themselves both radialists and femoralists; however, it is 
important to note that some providers, as many as 18%, still strongly favor femoral access 
(Nelson et al., 2018).  While the benefits of radial access are well known, femoral access is the 
preferred approach for patients with cardiogenic shock, left main or bifurcation PCI, and 
procedures with mechanical circulatory support (Nelson et al., 2018).  Other patient populations 
in which operators preferred femoral access include end-stage renal disease, known chronic total 
occlusion (CTO), concurrent right heart catheterization, history of coronary artery bypass grafts 
(CABG), need for rotational atherectomy, and an anticipated need for a sheath larger than 6F 
(Nelson et al., 2018).   
 Useful strategies for decreasing bleeding complications associated with transfemoral 
access include: the routine use of a bleeding risk stratification tool, radial access if possible, 
lower activated clotting time (ACT) goals, use of bivalirudin for high-risk bleeding scores, 
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judicious and selective use of glycoprotein inhibitors, use of fluoroscopy, ultrasound and 
micropuncture needle when gaining femoral access, early sheath removal and the use of vascular 
closure devices (Kerl et al., 2015; Mehran et al., 2010; Nelson et al., 2018; Pasala et al., 2016; 
Rashid et al., 2017; Singh, 2015).  However, Nelson et al. (2018) found in their 2016 survey that, 
despite best practice guidelines, 60% of the respondents preferred to use palpation alone when 
gaining femoral artery access, only 28% utilized fluoroscopy, and only 12% reported using 
ultrasound guidance (Nelson et al., 2018).  Furthermore, Nelson et al. (2018) reported that two-
thirds of their respondents indicated that they never use micropuncture needle kits, a very small 
needle which reduces trauma to the artery, when gaining transfemoral access (Murarka and 
Movahed, 2014).  
Antithrombotic Therapy in Percutaneous Coronary Intervention 
Both elective PCI procedures and those in the setting of ACS are associated with a high 
risk of thrombotic complications (Chaudry et al., 2018; Gargiulo et al., 2018; Grajek et al., 2018; 
Jaswaney et al., 2018; Mina et al., 2016).  Evidence of the most effective pharmacotherapy to 
successfully reduce thrombotic complications while minimizing the risk of bleeding 
complications remains ambiguous.  Antithrombotic therapy continues to evolve with newer, 
more potent medications available on the market and the measuring and comparing of these 
pharmacological strategies are further complicated by the evolution of drug-eluting coronary 
stents.  Current best practice guidelines include both the use of heparin and bivalirudin for 
prevention of stent thrombosis and subsequent infarction; however, the clinical safety regarding 
hemorrhagic effects of these therapies is conflicting (Gargiulo et al., 2018; Grajek et al., 2018; 
Jaswaney et al., 2018; Kerl et al., 2015; Mina et al., 2016; Nairooz et al., 2014; Pasala et al., 
2016; Saad et al., 2017; Shah et al., 2016).  The clinical decision of treatment with heparin versus 
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bivalirudin has long been debated.  Bivalirudin has been shown to be more efficient at preventing 
bleeding complications associated with PCI; however, there is conflicting evidence that there 
may be small, but possibly clinically significant, increase in thrombotic events (Gargiulo et al., 
2018; Jaswaney et al., 2018; Kerl et al., 2015; Mina et al., 2016; Pasala et al., 2016).  
Conversely, heparin appears to be sufficiently effective in preventing thrombotic events and has 
a significant financial advantage, but it has been associated with increased bleeding complication 
rates (Chaudry et al., 2018; Gargiulo et al. 2018; Jaswaney et al., 2018).  Historically, several 
major trials have provided conflicting support for both bivalirudin and heparin, prompting major 
swings in clinical use of each.  Currently, evidence is mounting that supports the use of 
bivalirudin specifically in high risk patient subsets to sufficiently prevent thrombotic events 
while mitigating the increased bleeding risk. 
Bivalirudin Use in High Risk Patient Subsets 
 Recent literature supports the use of bivalirudin when patients are identified as high risk 
by the NCDR PCI BRS and access will be gained via femoral artery (Kerl et al., 2015; Pasala et 
al., 2016; Singh, 2015).  However, it is important to understand that there is no benefit to using 
bivalirudin in procedures where radial access is utilized, even when the patient is identified as 
“high risk” by bleed risk stratification tools (Mina et al., 2016; Pasala et al., 2016).  
Agency Description 
Setting 
 The study took place in the Cardiac Cath Lab of a 555-bed acute care hospital located in 
the Midwest.  The unit has five Cath Lab suites with varying patient volume in each room, each 
day.  The Cath Lab management team consists of a manager, assistant manager, and three 
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coordinators. The lab is staffed by 21 nurses and 15 radiology technologists and there are 10 
interventional cardiologists who practice in this environment.  This lab completed 3251 left heart 
catheterizations in 2019, with 1529 of those proceeding to PCI.  
Target Population 
 The target population for this study is all patients undergoing PCI at this facility.  The 
study sample included PCI patients from three high volume physicians.  Post implementation, 
the physicians based their access approach and anticoagulation on the BRS, which is calculated 
pre-procedure and included in the Safety Time-Out.  Operators were asked to plan radial access 
when possible for patients who are considered high risk for bleeding complications (BRS 65 or 
greater).  If access was gained via femoral artery and the procedure proceeded to angioplasty, the 
physician was asked to choose bivalirudin for anticoagulation therapy in the high risk bleeding 
score population.   
Congruence with Institution’s Mission/Vision 
 The vision statement of the institution describes being a national leader of personalized 
patient experiences, clinical outcomes and affordable care.  The institution’s mission statement 
includes “providing exceptional outcomes and the finest experiences.”  It is important to note the 
hospital’s initiative to provide personalized health care, as this is precisely where this study’s 
aim is focused; individualizing access site and anticoagulation decisions based on specific patient 
characteristics and presentation.   
Stakeholders and Their Roles 
 Stakeholders of this research included patients at high risk for bleeding and their families, 
Cath Lab staff, pre-procedural nursing staff, interventional cardiologists, pharmacy staff, Cath 
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Lab administration, and hospital administration.  Patients presented for an elective, urgent or 
emergent cardiac catheterization and expected care to be personalized based on their needs.  
Patients who are at increased risk of bleeding can avoid major complications which are often 
associated with longer hospital stays, additional diagnostic testing, blood transfusions or 
subsequent procedures/surgeries.  Patients’ families also had a stakeholder role, as families are 
often secondarily affected by longer hospital stays, increased financial responsibilities, increased 
care requirements, and subsequent follow-up care appointments or procedures.  Pre-procedural 
nursing staff played an important role by completing the BRS calculator accurately and in a 
timely manner.  Clear understanding of the bleeding risk scoring tool was essential.  Accuracy 
was particularly important, as scoring one factor incorrectly could result in the patient being 
stratified in an inappropriate risk category.  Nursing staff within the Cath Lab played a 
significant role by identifying the high risk for bleeding population and collaborating with the 
physician regarding access site intention and anticoagulation strategy if the patient were to need 
PCI.   
Interventional cardiologists were a key stakeholder in this process, as the decisions to 
individualize patient care based on bleeding risk stratification lay with them.  Their personal 
RAB rate could be greatly impacted by a simple change in practice, making them more proficient 
in practice with fewer complications associated with their procedures.  Pharmacy staff had an 
important role as well, as the use of bivalirudin was low prior to this project, and could have 
increased with this research study.  It was important for the study to maintain an adequate supply 
of bivalirudin readily available in the Cath Lab suites.  The Cath Lab administration was an 
important stakeholder for this research study as well: it was important for them to maintain the 
highest level of safety for the patients in this environment.   With bleeding complications being 
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one of the most common life-threatening problems associated with this type of procedure, it was 
essential to mitigate the risk.  Another important stakeholder for this research was the hospital 
administration.  This is a relatively small private hospital which could be significantly affected 
by increased financial responsibility, significantly increased length of stay, and poor patient 
outcomes associated with bleeding complications. 
Barriers and Facilitators 
 Barriers are factors that prevent change from being successfully implemented.  For the 
purpose of this research major barriers included: (1) operator access site preference (2) increased 
cost of bivalirudin, (3) anatomical barriers to radial access site, (4) patient allergy listed to 
bivalirudin, (5) physician resistance, and (6) provider and nurse education.  
 Facilitators are factors that enhance successful implementation of change.  For this 
research, facilitators included: (1) the fact that BRS had previously been implemented at this 
facility and was currently being used; (2) the fact that BRS was already included in the pre-
procedure Safety Time-Out; (3) physician interest in decreasing publicly reported complication 
rates; (4) nurse interest in providing optimal patient care and outcomes; (5) administrative 
interest in providing safe, effective, and financially responsible care; and (6) the fact that patient 
data were already extracted in the CathPCI registry database. 
Project Design 
This pilot study involved a retrospective chart review with a pre/post design aimed at 
decreasing CathPCI Registry calculated RAB rates associated with PCI in a Midwestern acute 
care hospital.  This research had several specific aims: (1) determine if RAB rates are positively 
impacted by specifically identifying high risk bleeding patients and taking appropriate bleeding 
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precautions; (2) assess pre and post intervention prevalence of radial access use in the high 
bleeding risk population; (3) assess pre and post intervention anticoagulation strategies used; (4) 
assess physician reported barriers to optimizing bleeding reduction strategies; (5) assess the 
comorbidity burden by analyzing the impact of previously diagnosed diabetes mellitus, heart 
failure, end-stage renal disease, and obesity when bleeding events occur in the high risk bleeding 
population. 
Project Methods 
Evidence-Based Intervention 
Study physicians were asked to base access site decision and anticoagulation strategy on 
the patient’s calculated risk of bleeding.  Radial access was preferred in all patients with a high 
NCDR CathPCI BRS.  Patients with a high BRS who were not candidates for radial access 
(anatomically unattainable, procedures requiring large bore catheters, or by choice), received 
bivalirudin, unless contraindicated, as opposed to unfractionated heparin for anticoagulation.  
Procedures 
The NCDR CathPCI BRS (Table 1) is calculated by the pre-procedure area on all patients 
who undergo cardiac procedures at this institution.  To ensure accuracy, the procedure 
circulating nurse re-calculated the BRS for all patients who received care from the study 
interventionalist. Access site strategy was to be planned considering the patient’s BRS: radial 
access when at all possible for patients considered high risk of bleeding.  Patients with a known 
left internal mammary bypass graft were considered for access via left radial artery.  For patients 
who were undergoing right and left heart catheterizations; radial/brachial, radial/internal jugular, 
radial subclavian or even radial artery/femoral vein were preferred to femoral artery access.  If a 
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patient’s upper extremity arterial anatomy was unfavorable, or the provider anticipated using 
large bore equipment, femoral artery access was used.  If it was deemed necessary to access the 
femoral artery in a patient with a high BRS, the interventionalist was asked to utilize bivalirudin 
for anticoagulation if PCI was necessary (Figure 1).   
The Cath Lab nursing staff was asked to complete a brief survey (Figure 2) on every 
patient who had a procedure completed by the study interventionalists.  The survey was utilized 
to provide qualitative feedback regarding physician reported barriers to the process but was also 
designed to prompt nursing staff to consider the appropriate actions for high risk patients.   
IRB Approval Process 
Institutional Review Board (IRB) approval was obtained from both the University of 
Kentucky Medical Center and the study institution.  The University of Kentucky’s Office of 
Research Integrity approved the project via an expedited review process; informed consent was 
waived.  Subsequently, the project gained approval at the institution through the process of an 
IRB Reliance Agreement.   
Implementation  
Baseline data collection occurred from September 1st, 2019 through November 30th, 
2019.  Education of both the study interventionalists and the Cath Lab nurses occurred in 
November 2019.  Post implementation data were collected from December 1st, 2019 through 
February 29th, 2020.  
Education began with a thorough discussion with the three study physicians regarding the 
purpose and implications of the study and the decision tree for patients deemed at high risk for 
bleeding events according to the NCDR CathPCI BRS.  One on one teaching was completed 
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with each registered nurse in the Cath Lab regarding the need for BRS calculation confirmation 
and its implications.  Nurses were asked to address access site and potential anticoagulation 
strategy with the study physician prior to the start of the procedure.  In addition, nurses were 
asked to complete a brief information survey for each case completed by the study 
interventionalists.  
Sample 
The sample included all patients who underwent PCI performed by the pilot study 
interventional cardiologists from September 1st, 2019 to February 29th, 2020.  All PCIs are 
recorded in the CathPCI Registry; data from all the study physician cases were extracted for 
analysis.  The study excluded all patients who were considered STEMI and patients who were 
staged for CTO procedures.  
Measures and Instruments 
 Data collection was completed via NCDR CathPCI Registry data extraction and chart 
reviews by the investigator.  Appropriate subjects (PCIs performed by the study 
interventionalists) were identified from the registry database.  Variables that were included and 
extracted from the database consisted of: medical record number, gender, age, arterial access 
site, acute coronary syndrome, bleeding event, blood transfusion, the use of a vascular closure 
device, and presence of diabetes mellitus, heart failure, or end-stage renal disease.  Variables 
which were manually extracted from medical chart review included: NCDR PCI BRS, intra-
procedure anticoagulation, P2Y12 inhibitor used, use of GPIIbIIIa inhibitors, and the use of 
ultrasound for femoral access.  Surveys completed by the Cath Lab nursing staff were reviewed 
by the investigator when the study time frame was completed.  Data analysis was completed 
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utilizing SPSS data analytic software.  Chi square testing was completed to compare variables 
between the baseline and post implementation data.   
Results 
Sample Characteristics  
The baseline data consisted of 106 PCIs among the three study operators.  Of the baseline 
data PCIs, 15 were considered high risk per the risk stratification procedure.  There were 29 CTO 
procedures and 4 STEMIs, which were excluded.  Subsequently, only 10 patients could be used 
for data analysis after excluding CTO and STEMI (Table 2).  
In the post implementation time frame, there were 56 PCIs among the three 
interventionalists, and this group included 10 high bleeding risk patients.  The post 
implementation data set had 18 CTOs and 5 STEMIs which were excluded from data analysis.  
Ultimately, 6 patients were included for data analysis (Table 2).   
Of the patients in the baseline data, there were two bleeding “events” as classified by the 
NCDR CathPCI Registry, and three patients received blood transfusions; however, these patients 
were excluded from the data analysis due to exclusion criteria.  Among the patients in the post 
implementation data set, there were two with bleeding events, of which one received a blood 
transfusion; however, one was excluded due to CTO procedure and the other was not a high risk 
patient.  Consequently, no bleeding events or blood transfusions were recorded on patients who 
were used in data analysis in either group.   
Despite the difference in PCI sample size variation, it is significant to note that the 
inclusion sample was a similar proportion in each group.  Of the 106 baseline data PCIs, 10 
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patients were used (9.4%); of the 56 post implementation PCIs, 6 patients were used for data 
analysis (10.7%). 
Sample Demographics  
 Demographics that were evaluated for this study included age, gender, and BMI.  Ages of 
subjects in the baseline group ranged from 66 to 84 years old; ages in the post implementation 
group ranged from 60 to 91 years old.  In the pre-implementation group 9 out of 10 (90%) were 
female, whereas in the post implementation group 2 of 6 (33%) were female.  BMIs recorded in 
each group were similar.  Subjects with BMI between 20-30 comprised 60% and 50% of the pre 
and post samples respectively; BMI between 30-40 included 30% and 33%; and BMI of 40+ 
consisted of one patient in each sample,10% and 16.7% respectively. 
Risk-Adjusted Bleeding Rate 
 Among the patients who were considered at high risk for bleeding and included in the 
data analysis, there were no bleeding events recorded.  The RAB rate is calculated with the 
number of bleeding events as the numerator.  Due to the lack of bleeding events in the small 
sample analyzed, it is difficult to draw any conclusions regarding the RAB rate. 
Comorbidities 
 Comorbidities that were analyzed in this study included heart failure, diabetes mellitus, 
and end-stage renal disease.  These were included based on inclusion criteria of the NCDR 
CathPCI Registry.  Of the subjects in the baseline data, 50% had heart failure, 50% had diabetes 
mellitus, and none met the end-stage renal disease criteria.  Likewise, in the post implementation 
group, 50% had heart failure and 50% had diabetes mellitus; however, 2 patients (30%) did have 
end-stage renal disease.  
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Bleeding Avoidance Strategies 
 The BASs that this study examined included the use of radial artery access, the use of 
ultrasound when gaining femoral access, and the use of closure devices when femoral access was 
utilized.  Radial access was used in 30% of cases in the baseline data compared with 16% of 
cases in the post implementation group.  Ultrasound was utilized when gaining femoral access in 
100% of the cases examined in both groups.  The use of femoral artery closure devices increased 
after implementation; 29% and 40% in the baseline and post implementation groups, 
respectively.  
Pharmacological Strategies 
 The study analyzed three pharmacological strategies: intra-procedural anticoagulation, 
P2Y12 platelet inhibitor choice, and the use of GPIIbIIIa inhibitors.  Heparin was used for 
anticoagulation in 100% of subjects in the baseline data; bivalirudin was used in one of five 
femoral cases (20%) post implementation.  Ticagrelor was the P2Y12 platelet inhibitor of choice 
in the baseline group and was used in 80% of the cases; clopidogrel usage increased post 
implementation and was used 67% of the time.  GPIIbIIIa inhibitors were used less frequently in 
the post implementation group (17%) compared to the baseline group (40%). 
Physician Reported Barriers 
 Barriers to applying BAS were assessed utilizing a survey which was completed by the 
circulating nurse. Patient history of CABG was cited as the most common barrier to utilizing 
radial artery access.  Another frequently cited barrier to radial artery access was end stage renal 
disease with the presence of or anticipation of dialysis grafts or fistulas in the upper extremities.  
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Other barriers noted on the nurse completed survey included advanced age and previous radial 
access difficulties documented. 
Discussion 
 The sample sizes of both the baseline and post implementation groups were too small to 
show statistically significant levels of change post implementation.  Aside from gender, the 
demographics compared among the two groups were very similar, as was the measured 
comorbidities.  Because female gender increases the bleeding risk score, it was anticipated that 
there would be more females than males in the high risk subset.  The post implementation group 
had fewer females proportionately; however, there was more end-stage renal disease, which 
likely contributed to the shift.   
 There were no bleeding events recorded in either high-risk group, making it difficult to 
draw any conclusions associating individualized access site and anticoagulation strategies with 
decreased bleeding events.  When considering the entire group of PCIs completed by the study 
interventionalists, there were two bleeding events recorded in the pre-implementation group: one 
which was stratified as high risk but presented as a STEMI and therefore was excluded, and 
another which was stratified as intermediate bleeding risk but was also a staged CTO procedure, 
which was an exclusion criterion as well. 
 This study specifically suggested the use of radial access and use of bivalirudin if PCI is 
performed via femoral access in the high bleeding risk population.  Again, small sample sizes 
limit the significance of the findings.  Radial access decreased proportionately post 
implementation.  While this initially appears discouraging, feedback from the nurse survey 
indicated that three of the six patients were either hemodialysis patients with grafts or fistulas in 
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upper extremities, or peritoneal dialysis patients in which upper extremities are often preserved 
for the possibility of future upper extremity dialysis access placement.  One of the six subjects in 
the post implementation group were accessed radially.  One of the five post implementation 
subjects who was accessed via femoral artery did receive bivalirudin as opposed to heparin for 
anticoagulation, and it was specifically documented in the procedural report that bivalirudin was 
chosen due to the high bleeding risk.   
 There were encouraging secondary findings related to bleeding avoidance and 
anticoagulation strategies.  The operators who participated in this study have excellent habits of 
utilizing ultrasound for femoral artery access.  Ultrasound use was documented in 100% of all 
femoral PCI cases in both the baseline and post implementation data sets.  Although the sample 
sizes are too small to be statistically significant, there was an increased use of femoral vascular 
closure devices.  It is also important to note the decrease in GPIIbIIIa inhibitors and the 
increased use of clopidogrel as opposed to ticagrelor.  
Implications for Future Nursing Research 
 The results of this study suggest several implications for the future of research on this 
topic.  First, it would be important to expand data collection to increase high bleeding risk 
sample sizes.  If continuing with one institution, there are multiple ways one could increase 
inclusion criteria to capture more high risk subjects.  Expanding to include diagnostic procedures 
would give helpful insight to operator bleeding avoidance habits with the exception of 
anticoagulation strategies.  Including all interventional cardiologists, CTO procedures, STEMI 
cases, and collecting data over longer periods of time are all suggestions to increase inclusion for 
a single center study.  Another expansion opportunity in future research is the inclusion of 
intermediate bleeding risk patients.  Singh (2015) discusses the importance of mitigating 
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bleeding risk with BAS in both the intermediate and high-risk populations; however, it is 
important to note that current research does not suggest the use of bivalirudin in the intermediate 
risk population. 
 To encourage and measure the use of bleeding avoidance strategies, researchers might 
also consider focusing on one strategy at a time with all interventional cardiologists in a single 
center.  Perhaps evidence-based education for all interventionalists and staff on one bleeding 
avoidance focus point and monitoring that variable for a period would be more influential.   
 The institution where this study took place has, since implementation, shifted from 
measuring bleeding complications with RAB rates to monitoring bleeding events by capturing 
patients who have received blood transfusions post procedure.  With this new technique, the 
institution does not rely on the NCDR CathPCI Registry bleeding event criteria; instead, they are 
investigating all patients who receive post procedure transfusions.  Future research could include 
examining these post procedure transfusion cases to determine if the bleeding risk stratification 
tool is capturing the patients who require blood transfusions as high risk.  
Limitations 
 This study had numerous limitations.  The study was a pilot study completed at a single 
center, which limited the sample size.  The nature of the high bleeding risk subset the study 
aimed to investigate narrowed the sample size for data analysis dramatically.  The data were 
collected over a short period of time, further limiting the sample size.  During the post 
implementation phase of the data collection, one interventionalist stepped away from the Cath 
Lab environment, adding an additional challenge to the sample size.   Small sample sizes limit 
the ability to find significance and generalize findings in these data. 
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 Again, the lack of bleeding events among the high risk patients analyzed limits the ability 
to draw any conclusions regarding individualized access site and anticoagulation strategies to 
decrease bleeding events. 
Conclusion 
 Bleeding and vascular complications are potentially preventable and have significant 
consequences.  The ACC recommends using risk stratification tools to identify patients at high 
bleeding risk and strategies to decrease access site complications have been thoroughly studied.  
Bleeding avoidance strategies that have the potential to impact patient outcomes are readily 
available and are inexpensive when compared to potential complications, yet they require 
behavior and strategy modifications among interventional cardiologists.   
The aim of this study was to determine if individualizing patient care according to their 
bleeding risk stratification would be beneficial in preventing bleeding complications associated 
with PCI.  While this study was able to provide insight into the high bleeding risk population, its 
proportion among PCIs, and its characteristics, small sample size limited its ability to reach 
significant conclusions related to its objectives.  Further research is necessary to directly 
correlate the benefits of individualizing patient care based on bleeding risk stratification. 
Through the continued study of this patient population we can continue to provide individualized 
evidence based practice for high bleeding risk patients.  
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Table 1: NCDR CathPCI Bleeding Risk Score 
STEMI  No 
0 
Yes 
15 
  
Age < 60 
0 
60-70 
10 
71-79 
15 
> 80 
20 
BMI < 20 
15 
20-30 
5 
31-39 
0 
≥ 40 
5 
Previous PCI No 
10 
Yes 
0 
  
Chronic 
Kidney Disease 
No 
0 
Mild 
10 
Moderate 
25 
Dialysis 
30 
Shock No 
0 
Yes 
35 
  
Cardiac arrest 
within 24 hour 
No 
0 
Yes 
15 
  
Female No 
0 
Yes 
20 
  
Hb Hb < 13 
5 
13 ≤ Hb < 15 
0 
Hb ≥ 15 
10 
 
PCI Status Elective 
0 
Urgent 
20 
Emergency/Salvage 
> 40 
 
Bleeding Risk 
(Total) 
< 25 
Low 
25-65 
Intermediate 
> 65 
High 
 
 
Table 2: Sample Characteristics 
 
 Pre 
 
Post 
Total PCI 106 56 
High Risk (all) 15 10 
CTO (Excluded) 29 18 
STEMI (Excluded) 4 5 
High Risk excluding CTO 
& STEMI 
10 6 
Bleeding Events 0 0 
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Figure 1:  High Risk Access Site and Anticoagulation Strategy 
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Figure 2:  RN Data Collection Form 
 
 
 
 
 
 
High Bleeding Risk?   (if no, stop here) 
 Yes     No 
Radial Approach? 
 Yes  No 
If not radial, was bivalirudin (Angiomax) utilized for PCI? 
 Yes  No  N/A 
Barriers to radial approach (if not utilized)? 
 _________________________________ 
Any known bleeding complications at the conclusion of the case? 
 Yes  No 
 Brief Description ________________________________ 
 
 
 
 
 
 
 
Patient Label 
